nucleosome diagnostics VolitionRx Signs on Diagnostic Oncology CRO for Clinical Studies of Cancer, Sepsis Tests DXOCRO will conduct large-scale clinical utility studies of Volition's Nu.Q NETs and Nu.Q Cancer tests at multiple sites in the US. VolitionRx Secures $1.5M Loan From Namur Invest Capital Risk The non-dilutive funding will go toward an early-access program for Volition's Nu.Q nucleosome quantification technology in the US, EU, and UK. VolitionRx Signs on Sage Healthcare as Distributor for Canine Cancer Test in Asia The Nu.Q Vet Cancer Test is an ELISA-based blood test that identifies and measures circulating nucleosomes, an early cancer marker. Delfi Diagnostics Nets $100M in Series A Financing, Plans Multi-Cancer Screening Test The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening. VolitionRx, 4D Lifetec Partner to Combine Early Cancer Detection Assays The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients. Jun 24, 2020 Stanford Team Debuts EPIC-Seq Method to Detect, Classify Cancer From cfDNA Fragment Patterns May 9, 2018 VolitionRx, Active Motif Sign Global Sales, Distribution Agreement May 12, 2016 VolitionRx Launches Clinical Trial in Germany for Pancreatic Cancer Blood Test Sep 22, 2015 VolitionRx Receives CE Mark for Colorectal Cancer Diagnosis Assay Mar 5, 2015 VolitionRx, ImmuneHealth Collaborate on Prostate Cancer Study Feb 24, 2015 VolitionRx Acquires Nucleosome Analysis IP from Chroma Therapeutics Feb 6, 2015 VolitionRx Begins Trading on NYSE MKT, Prices Public Offering at $3.75 per Share Jan 21, 2015 VolitionRx, SGH Ink Deal for Study on Ovarian Cancer Using NuQ Assays Dec 17, 2014 U of Bonn Study to Assess VolitionRx Platform for Lung Cancer Dx Nov 11, 2014 VolitionRx Collaborates With University of Oxford on Endometriosis Biomarkers Study Sep 26, 2013 VolitionRx, Active Motif Ink Distribution Deal Jun 18, 2013 VolitionRx Eyes $1.5M Financing Round for Clinical Trials of Nucleosome-based Tests May 29, 2013 VolitionRx Reaches Deal with Hvidovre Hospital, University of Copenhagen for Colorectal Cancer Trials Feb 17, 2012 Abcodia, VolitionRx Collaborate on Nucleosome-based Dx for Cancer Breaking News Cancer Prognoses Informed by Module-Based Approach, Study Finds People in the News at Illumina, Centogene, BioSkryb New Products Posted to GenomeWeb: Bio-Rad, BD, Analytik Jena, BioMérieux Genetic Technologies to Raise A$5M in Direct Stock Offering In Brief This Week: SD Biosensors, Meridian, Oncocyte, Opko Health, GeneDx, More The Scan Study Reveals New Details About Genetics of Major Cause of Female Infertility Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency. Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis. Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven. White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.